Does US FDA Need An Independent Commission To Analyze Its Pandemic Response?
Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.
You may also be interested in...
Early conversations on clinical trial endpoints were particularly helpful in developing Comirnaty, a Pfizer executive said. Whether sponsors can continue to get such discussions may go a long way in determining whether a new generation of products is developed.
Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.
Stakeholders believe virtual meetings should remain an option going forward, but that in-person sessions should still be convened in many cases.